| Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance D Staudt, HC Murray, T McLachlan, F Alvaro, AK Enjeti, NM Verrills, ... International journal of molecular sciences 19 (10), 3198, 2018 | 79 | 2018 |
| Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in … MV Antunes, S Raymundo, V de Oliveira, DE Staudt, G Gössling, ... Talanta 132, 775-784, 2015 | 61 | 2015 |
| Influence of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D status on tamoxifen biotransformation MV Antunes, TA da Fontoura Timm, V de Oliveira, DE Staudt, ... Therapeutic drug monitoring 37 (6), 733-744, 2015 | 40 | 2015 |
| Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma RJ Duchatel, A Mannan, AS Woldu, T Hawtrey, PA Hindley, AM Douglas, ... Neuro-oncology advances 3 (1), vdab169, 2021 | 39 | 2021 |
| ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma ER Jackson, RJ Duchatel, DE Staudt, ML Persson, A Mannan, S Yadavilli, ... Cancer research 83 (14), 2421-2437, 2023 | 33 | 2023 |
| CYP3A4*22 is Related to Increased Plasma Levels of 4-Hydroxytamoxifen and Partially Compensates for Reduced CYP2D6 Activation of Tamoxifen MV Antunes, V De Oliveira, S Raymundo, DE Staudt, G Gössling, ... Pharmacogenomics 16 (6), 601-617, 2015 | 32 | 2015 |
| B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers T McLachlan, WC Matthews, ER Jackson, DE Staudt, AM Douglas, ... Molecular Cancer Research 20 (12), 1711-1723, 2022 | 16 | 2022 |
| Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients MV Antunes, DE Staudt, S Raymundo, V de Oliveira, G Gössling, R Pirolli, ... Clinical biochemistry 47 (12), 1084-1090, 2014 | 12 | 2014 |
| Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... Science Signaling 16 (778), eabp9586, 2023 | 10 | 2023 |
| CAR T cell therapies for diffuse midline glioma BC Thomas, DE Staudt, AM Douglas, M Monje, NA Vitanza, MD Dun Trends in cancer, 2023 | 9 | 2023 |
| PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, SG Parackal, D Kiltschewskij, IJ Findlay, ... The Journal of clinical investigation 134 (6), 2024 | 5 | 2024 |
| Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... Clinical Proteomics 19 (1), 48, 2022 | 5 | 2022 |
| DIPG-29. Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) inhibition drives protein kinase c activation (PKC) in diffuse intrinsic pontine glioma (DIPG) RJ Duchatel, A Mannan, ER Jackson, D Staudt, DA Skerrett-Byrne, ... Neuro-oncology 22 (Supplement_3), iii292-iii293, 2020 | 3 | 2020 |
| Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection (vol 19, 48, 2022) DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... CLINICAL PROTEOMICS 20 (1), 2023 | 1 | 2023 |
| Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... bioRxiv, 2022.03. 09.483687, 2022 | 1 | 2022 |
| DIPG-88. TARGETING THE ANTIOXIDANT RESPONSE ELEMENT AXIS SENSITIZES DIFFUSE MIDLINE GLIOMA CELLS TO ONC201 ER Jackson, RJ Duchatel, CJ Fish, ML Persson, DE Staudt, IJ Findlay, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| DIPG-06. FUNCTIONAL MULTI-OMIC PROFILING OF THE LANDSCAPE OF DIFFUSE MIDLINE GLIOMAS TO IDENTIFY THERAPEUTIC VULNERABILITIES IJ Findlay, D Staudt, RJ Duchatel, ER Jackson, P Kearny, ML Persson, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling DE Staudt, ZP Germon, A Mannan, T McLachlan, HC Murray, RJ Duchatel, ... bioRxiv, 2024.07. 26.605229, 2024 | | 2024 |
| EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL … E Jackson, R Duchatel, D Staudt, M Persson, A Mannan, S Yadavilli, ... Neuro-Oncology 25 (Supplement_5), v232-v232, 2023 | | 2023 |
| EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA R Duchatel, E Jackson, S Parackal, C Sun, P Daniel, A Mannan, I Findlay, ... Neuro-Oncology 25 (Supplement_5), v230-v231, 2023 | | 2023 |
